An Open-Label, Long-Term Extension Study of the Safety and Efficacy of A Long-acting Human Growth Hormone (VRS-317) in Children with Growth Hormone Deficiency

Investigator: Stephen M. Rosenthal, MD
Sponsor: Versartis, Inc

Location(s): United States


Protocol 13VR3 is designed as an open-label extension study assessing long-term VRS-317 administration. It is open to subjects completing a Versartis Phase 2 or 3 study in children with growth hormone deficiency.